Today, Clinical Trials often span investigational sites across multiple continents, including Europe, use laboratories in North America, and have data stored in Asia. For Contract Research Organizations (CROs) at the heart of these operations, this global footprint brings a real challenge: processing large volumes of sensitive personal data while remaining compliant with a growing number of Data Protection laws. In this landscape, Codes of Conduct, particularly the authority-approved EUCROF GDPR Code of Conduct (the Code), emerge as powerful tools to help CROs harmonize their practices, demonstrate accountability, and build trust with sponsors, regulators, and trial participants.
⚠️ The Growing Compliance Burden on CROs
CROs are considered data processors under the GDPR, handling health-related personal data on behalf of sponsors in the conduct of Clinical Trials. This role carries significant obligations, including implementing sufficient Technical and Organizational Measures to ensure the security of processing, managing sub-processors to meet the same requirements, maintaining records of processing activities, and supporting Sponsors in conducting Data Protection Impact Assessments, responding to data breaches, and handling data subject requests, where applicable.
Beyond Europe, China’s Personal Information Protection Law (PIPL) imposes strict controls on cross-border data transfers, while Brazil’s LGPD and India’s Digital Personal Data Protection Act each introduce additional requirements. Canada and the United States add further complexity through evolving provincial and state-level frameworks.
For CROs, especially micro, small, and medium-sized enterprises, keeping pace with this regulatory fragmentation is a significant burden. Divergent national interpretations of the GDPR can lead to inconsistent compliance practices across Clinical Trial sites, creating risks for both CROs and their customers, namely Clinical Trial sponsors.
📖 What Is a GDPR Code of Conduct?
Article 40 of the GDPR explicitly encourages industry associations to develop Codes of Conduct that translate the GDPR’s key principles into practical, sector-specific standards. An approved Code is not merely a best-practice guideline; it is a formal accountability mechanism overseen by an accredited monitoring body and recognized by supervisory authorities.
Adherence can serve as evidence of compliance under Article 32 (security of processing) and may also be considered a mitigating factor when authorities assess sanctions under Article 83. For data processors such as CROs, the Code provides a recognized way to demonstrate to sponsors that their Data Protection standards meet an acknowledged benchmark.
In addition, where a CRO adheres to the Code as a processor, its customers (acting as controllers) may rely on that adherence to support their assessment that the processor provides sufficient guarantees under Article 28 GDPR. As a result, they may streamline or reduce the scope of their vendor due diligence and privacy assessment processes.
🇪🇺 The EUCROF Code of Conduct: The First EU Compliance Tool for Clinical Research
On September 12, 2024, the French Data Protection Authority (CNIL) officially approved the European CRO Federation (EUCROF) GDPR Code of Conduct for Service Providers in Clinical Research, following a positive opinion from the European Data Protection Board (EDPB). This makes it the first transnational Code of Conduct in the health sector, applicable across all 27 EU Member States.
The Code covers 23 categories of clinical services typically delivered by CROs and addresses the personal data of EU study participants and healthcare professionals in both interventional and non-interventional studies. In early 2026, the CNIL also approved the monitoring body (COSUP) and its operating procedures, thereby making the Code fully operational.
Adherence follows a structured process established by EUCROF. CROs complete a compliance dossier reviewed by the Code’s Supervisory Committee (COSUP), and successful adherence results in the award of a Compliance Mark, either Level 1 or Level 2, valid for three years.
MyData-TRUST is particularly proud to have contributed to the development of this landmark initiative as part of the working group behind the Code. This involvement has been further reinforced by the appointment of its Chief Operating Officer as a member of COSUP, positioning MyData-TRUST at the forefront of Data Protection governance in Clinical Research.
🎯 Why Should CROs Adopt the Code?
Stronger accountability.
Adherence is explicitly recognized by the GDPR as a means of demonstrating compliance and providing sufficient guarantees regarding the security of processing for sponsors, participants, and regulators. For CROs operating in Europe, adherence supports inspection readiness and strengthens Data Protection compliance practices.
Harmonized compliance.
Before the EUCROF Code, each sponsor applied its own criteria for evaluating a CRO’s Data Protection compliance, requiring CROs to respond to a wide range of assessment methodologies. The Code provides a single, recognized reference framework that can replace this fragmented approach. While achieving truly global compliance remains a challenge, the Code enables a unified and consistent approach across all EU Member States.
Broad applicability.
Consistent with the material and territorial scope of Articles 2 and 3 of the GDPR, the Code also applies to non-EU CROs and Clinical Research service providers conducting global Clinical Trials involving European sites.
Competitive edge.
The official Compliance Mark provides organizations with a visible signal of trustworthiness. Even for smaller CROs competing against larger organizations, this can be a decisive factor during sponsor selection and procurement processes.
Practical guidance for SMEs.
The approved Code provides a ready-to-implement compliance framework, including a dedicated compliance control matrix, reducing the burden on smaller organizations that may lack the resources to build a comprehensive Data Protection program from the ground up.
📈 Looking Ahead: From Compliance to Competitive Advantage
While the Code is rooted in the GDPR, the governance structure it establishes requires systematic risk assessments, effective and documented security measures, and practical sub-processor management. Together, these elements create a compliance foundation that can be extended to meet the requirements of other jurisdictions.
As the Code’s monitoring body begins its activities and the first adherents earn their Compliance Marks, we believe the standard for Data Protection compliance across the Clinical Research industry will continue to rise.
With increasing participant trust, growing regulatory scrutiny, and expanding data volumes in the world of Clinical Research, the Code is no longer a nice-to-have. It has become a strategic necessity.
For CROs looking to thrive in this environment, the question is no longer whether to adopt a Code of Conduct, but how quickly they can take action to achieve adherence.
MyData-TRUST with its in-depth, insider knowledge of the EUCROF Code of Conduct, is a go-to partner to support your preparation journey. Our team guides you from readiness assessments through to full adherence, helping you not only achieve compliance but turn it into a tangible competitive advantage…
Author: Xiaolan Xiao
